TAOX · TAO Synergies Inc.

Net income plunged to -$28.7M, a -125.1% YoY change from -$12.8M in FY 2024, with diluted EPS falling to $-8.81 from $10.99 (-180.2% YoY). Management attributes the increased loss primarily to higher other loss, G&A expenses, and warrant issuance costs, again tempered by reduced R&D outlays. This dynamic illustrates the volatility introduced by the TAO accumulation strategy, where excess cash—defined as amounts beyond the estimated needs for 1.5 to 2.0 years of projected operating and working capital—is deployed into TAO holdings. Actual allocation levels vary based on market conditions, TAO pricing, liquidity requirements, and other management considerations, emphasizing a disciplined yet flexible approach to digital asset exposure.

Cash flow from operations reflected -$6.4M used, accelerating from -$4.9M in the prior year, aligning with the company's history of negative operating cash flows since inception. This burn rate supports ongoing development efforts, including potential future increases in other development expenses as resources allow to advance therapeutic products for AD and beyond. Management views TAO as long-term holdings and plans continued accumulation over time, positioning the treasury as a hedge against traditional biopharma risks while funding innovation.

Liquidity management remains central, with cash assets exceeding baseline requirements earmarked for TAO purchases. The company expects to sustain expenses, losses, and negative operating cash flows over at least the next several years to pursue product development. External factors, such as regulatory measures, could pressure future product demand or pricing once approvals are secured (Item 1). This FY 2025 10-K underscores TAO Synergies' evolution into a hybrid biopharma-crypto entity, where TAO strategy drives revenue diversification but amplifies earnings volatility through mark-to-market dynamics and pivot-related costs.